PIA
SYRS

Piedmont Investment Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Piedmont Investment Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-43
Closed -$4K – 2370
2018
Q2 		$4K Buy
+43
New +$5.33K ﹤0.01% 2291

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Piedmont Investment Advisors's SYRS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2018, closing a stake of 43 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in SYRS in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 76 funds tracked by Wall St. Rank hold SYRS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 43 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $4K in Q2 2018.
  • 76 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.